Exacerbations of chronic obstructive pulmonary disease and cardiac events a post hoc cohort analysis from the SUMMIT randomized clinical trial

Ken M. Kunisaki, Mark T. Dransfield, Julie A. Anderson, Robert D. Brook, Peter M.A. Calverley, Bartolome R. Celli, Courtney Crim, Benjamin F. Hartley, Fernando J. Martinez, David E. Newby, Alexa A. Pragman, Jørgen Vestbo, Julie C. Yates, Dennis E. Niewoehner

Research output: Contribution to journalArticlepeer-review

183 Scopus citations

Abstract

Rationale: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are common, associated with acute inflammation, and may increase subsequent cardiovascular disease (CVD) risk. Objectives: Determine whether AECOPD events are associated with increased risk of subsequent CVD. Methods: We performed a secondary cohort analysis of the SUMMIT (Study to Understand Mortality and Morbidity) trial, a convenience sample of current/former smokers with moderate COPD from 1,368 centers in 43 countries. All had CVD or increased CVD risk. AECOPD was defined as an increase in respiratory symptoms requiring treatment with antibiotics, systemic corticosteroids, and/or hospitalization.CVDevents were a composite outcome of cardiovascular death, myocardial infarction, stroke, unstable angina, and transient ischemic attack. All CVD events were adjudicated. Cox proportional hazards models compared the hazard for a CVD event before AECOPD versus after AECOPD. Measurements and Main Results: Among 16,485 participants in SUMMIT, 4,704 participants had at least one AECOPD and 688 had at least one CVD event. The hazard ratio (HR) for CVD events after AECOPD was increased, particularly in the first 30 days after AECOPD (HR, 3.8; 95% confidence interval, 2.7-5.5) and was elevated up to 1 year after AECOPD. The 30-day HR after hospitalized AECOPD was more than twofold greater (HR, 9.9; 95% confidence interval, 6.6-14.9). Conclusions: In patients with COPD with CVD or risk factors for CVD, exacerbations confer an increased risk of subsequent CVD events, especially in hospitalized patients and within the first 30 days after exacerbation. Patients and clinicians should have heightened vigilance for early CVD events after AECOPD. Clinical trial registered with www.clinicaltrials.gov (NCT 01313676).

Original languageEnglish (US)
Pages (from-to)51-57
Number of pages7
JournalAmerican journal of respiratory and critical care medicine
Volume198
Issue number1
DOIs
StatePublished - Jul 1 2018

Bibliographical note

Funding Information:
Supported by GlaxoSmithKline, which provided funding for the original SUMMIT trial (NCT01313676) (GSK113782). GlaxoSmithKline employees performed the statistical analysis and participated in the writing group team, but GlaxoSmithKline did not direct or make final decisions regarding study conception, analysis of results, manuscript writing, or the decision to submit for publication. The views expressed in this article are those of the authors and do not reflect the views of the U.S. government, the Department of Veterans Affairs, the funders, the sponsors, or any of the authors’ affiliated academic institutions.

Keywords

  • Cardiovascular diseases
  • Chronic obstructive pulmonary disease
  • Cohort study

Fingerprint

Dive into the research topics of 'Exacerbations of chronic obstructive pulmonary disease and cardiac events a post hoc cohort analysis from the SUMMIT randomized clinical trial'. Together they form a unique fingerprint.

Cite this